A Prospective Evaluation of Health Services Outcomes & Emerging

Status Active, not recruiting

Clinical Trial Summary

The primary aim of the proposed research is to examine the relationship of lifestyle changes to new dietary, biomedical, and cellular parameters among new enrollees entering the "Dr. Dean Ornish Program for Reversing Heart Disease program" at 5 selected sites. Specifically, the investigators will add assessments of emerging cardiac risk factors (e.g., high sensitivity C-reactive protein [hsCRP], fibrinogen, lipoprotein(a) [Lp(a)], small, dense LDL, apolipoprotein B [apoB], apolipoprotein A-I [apo A1], the apoB/apoA1 ratio, homocysteine [Hcy], B-type natriuretic peptide [BNP], oxidized LDL, fasting insulin and waist-to-hip ratio [WHR]), protective and pathogenic dietary markers (e.g., folate, carotenoids, trans fatty acids), and measures of social support and cognitive functioning to the already existing assessment variables in the Multisite Cardiac Lifestyle Intervention Program (MCLIP).

Hypothesis 1: Participation in the lifestyle program will not only be associated with favorable changes in standard coronary risk factors and quality of life, but also with improvements in emerging cardiac risk factors [hsCRP, Hcy, BNP, fibrinogen, Lp(a), small, dense LDL, apoB, apoA1, oxidized LDL, fasting insulin, and abdominal obesity] and psychosocial well-being (i.e., social support, and cognitive functioning).

Hypothesis 2: High intake of emerging protective dietary factors and low intake of emerging pathogenic dietary factors will be associated with improvements in both standard and emerging cardiac risk factors (e.g. Hcy, oxidized LDL).

Hypothesis 3: Degree of adherence to the lifestyle change program will be associated with differential improvement in standard coronary risk factors, emerging risk factors, cellular aging, and psychosocial variables.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00820313
Study type	Interventional
Source	Preventive Medicine Research Institute
Contact
Status	Active, not recruiting
Phase	N/A
Start date	October 2006
Completion date	May 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05196659` - Collaborative Quality Improvement (C-QIP) Study	N/A
Completed	`NCT05088291` - Application of a New X-ray Protective Device in Coronary Interventional Therapy
Completed	`NCT03076801` - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?	N/A
Completed	`NCT04584645` - A Digital Flu Intervention for People With Cardiovascular Conditions	N/A
Not yet recruiting	`NCT04995159` - Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System	N/A
Recruiting	`NCT02967718` - Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome	N/A
Completed	`NCT02888652` - Study on the Registration of Coronary Heart Disease Patients Undergoing PCI
Completed	`NCT02163044` - The Hellenic Postprandial Lipemia Study (HPLS)
Terminated	`NCT02045134` - Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery	N/A
Active, not recruiting	`NCT02244853` - Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease	N/A
Completed	`NCT02440893` - Understanding the Effect of Metformin on Corus CAD (or ASGES)
Terminated	`NCT01906957` - Cognition and Exercise Training	N/A
Completed	`NCT02753829` - Home-based Cardiovascular Rehabilitation, Maintenance Phase, in Subjects With Coronary Artery Disease	N/A
Completed	`NCT01826552` - Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent	Phase 4
Completed	`NCT01920009` - Impact of Motivational Interviews Within Pharmacy Care Upon Adherence to Cardiovascular Medicines	N/A
Recruiting	`NCT01689688` - Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography	N/A
Completed	`NCT01779401` - Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients	N/A
Recruiting	`NCT01456364` - Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing	Phase 4
Recruiting	`NCT01462799` - COR-PRIM: Problem-based Learning (PBL) After Coronary Heart Disease (CHD) - Long-term Evaluation in Primary Care of Self-care	N/A
Completed	`NCT01428947` - Does Coronary Angiography Cause Cognitive Dysfunction?	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Prospective Evaluation of Health Services Outcomes and Emerging Cardiovascular Disease Biomarkers

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms